Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
TiNivo-2: Tivozanib + Nivolumab vs Tivozanib in Advanced RCC
NCT04987203Phase 3Completed
- Sponsor
- AVEO Oncology
- Start
- Sep 2021
- Primary completion
- Jan 2026
- Modality
- Fragment-Derived Small Molecules, Monoclonal Antibodies, Allosteric Modulators
- Countries
- 16
01
Overview
A Phase 3 trial of tivozanib, nivolumab in renal cell carcinoma (RCC), sponsored by AVEO Oncology. Started Sep 2021; status: completed.
02
Drugs
tivozanibnivolumab
03
Conditions
renal cell carcinoma (RCC)
Beyond the preview
Go deeper on NCT04987203.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04987203.